Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1077

1.

Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials.

Hanif H, Belley-Cote EP, Alotaibi A, Dvirnik N, Neupane B, Beyene J, Eikelboom JW, Holmes D, Whitlock RP.

J Cardiovasc Surg (Torino). 2017 Feb 17. doi: 10.23736/S0021-9509.17.09824-X. [Epub ahead of print]

PMID:
28215062
2.

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis.

Bai Y, Deng H, Shantsila A, Lip GY.

Stroke. 2017 Feb 17. pii: STROKEAHA.116.016275. doi: 10.1161/STROKEAHA.116.016275. [Epub ahead of print]

PMID:
28213573
3.

Warfarin dosing algorithms under-predict dose requirements in patients requiring ≥ 7mg daily: A systematic review and meta-analysis.

Saffian SM, Duffull SB, Wright DF.

Clin Pharmacol Ther. 2017 Feb 4. doi: 10.1002/cpt.649. [Epub ahead of print]

PMID:
28160278
4.

Safety of Endovascular Intervention for Stroke on Therapeutic Anticoagulation: Multicenter Cohort Study and Meta-Analysis.

Kurowski D, Jonczak K, Shah Q, Yaghi S, Marshall RS, Ahmad H, McKinney J, Torres J, Ishida K, Cucchiara B.

J Stroke Cerebrovasc Dis. 2017 Jan 16. pii: S1052-3057(16)30635-8. doi: 10.1016/j.jstrokecerebrovasdis.2016.12.027. [Epub ahead of print]

PMID:
28110890
6.

Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials.

Ambrosi P, Daumas A, Villani P, Giorgi R.

Int J Cardiol. 2017 Mar 1;230:572-576. doi: 10.1016/j.ijcard.2016.12.055.

PMID:
28063671
7.

Extracranial arterial and venous thromboembolism in patients with atrial fibrillation: A meta-analysis of randomized controlled trials.

Wang KL, Büller HR, Goto S, Lin CY, Lai EY, Chiu CC, Chiang CE, Giugliano RP.

Heart Rhythm. 2017 Jan 4. pii: S1547-5271(16)31328-5. doi: 10.1016/j.hrthm.2016.12.038. [Epub ahead of print]

PMID:
28062249
8.

Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study.

Brunetti ND, Gesuete E, De Gennaro L, Correale M, Caldarola P, Gaglione A, Di Biase M.

Int J Cardiol. 2017 Mar 1;230:214-221. doi: 10.1016/j.ijcard.2016.12.168. Review.

PMID:
28062137
9.

Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.

Bundhun PK, Soogund MZ, Teeluck AR, Pursun M, Bhurtu A, Huang WQ.

BMC Cardiovasc Disord. 2017 Jan 6;17(1):15. doi: 10.1186/s12872-016-0449-2.

10.

Assessment of Patient Adherence to Direct Oral Anticoagulant vs Warfarin Therapy.

Patel SI, Cherington C, Scherber R, Barr K, McLemore R, Morisky DE, Cha S, Mookadam F, Shamoun F.

J Am Osteopath Assoc. 2017 Jan 1;117(1):7-15. doi: 10.7556/jaoa.2017.002.

PMID:
28055097
11.

Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials.

Patti G, Di Gioia G, Cavallari I, Nenna A.

Diabetes Metab Res Rev. 2016 Dec 28. doi: 10.1002/dmrr.2876. [Epub ahead of print] Review.

PMID:
28029216
12.

Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.

Kim S, Yun YM, Chae HJ, Cho HJ, Ji M, Kim IS, Wee KA, Lee W, Song SH, Woo HI, Lee SY, Chun S.

Ann Lab Med. 2017 Mar;37(2):180-193. doi: 10.3343/alm.2017.37.2.180.

13.

Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systemic review and meta-analysis of 53 studies
.

Tang W, Shi QP, Ding F, Yu ML, Hua J, Wang Y.

Int J Clin Pharmacol Ther. 2016 Dec 27. doi: 10.5414/CP202833. [Epub ahead of print]

PMID:
28025970
14.

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis.

Andò G, Capranzano P.

Int J Cardiol. 2017 Mar 15;231:162-169. doi: 10.1016/j.ijcard.2016.11.303.

PMID:
28007305
15.

Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review.

Owens RE, Kabra R, Oliphant CS.

Clin Cardiol. 2016 Dec 22. doi: 10.1002/clc.22659. [Epub ahead of print] Review.

16.

The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.

Bader LA, Elewa H.

PLoS One. 2016 Dec 19;11(12):e0168732. doi: 10.1371/journal.pone.0168732.

17.

Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis).

Guo L, Li S, Wang P, Zhong X, Hong Y.

Am J Cardiol. 2017 Feb 15;119(4):585-593. doi: 10.1016/j.amjcard.2016.11.006.

PMID:
27989309
18.

Safety of warfarin in "high-risk" populations: A meta-analysis of randomized and controlled trials.

Di Minno MN, Ambrosino P, Dentali F.

Thromb Res. 2017 Feb;150:1-7. doi: 10.1016/j.thromres.2016.12.005.

PMID:
27988374
19.

New Standards of Care in Ischemic Stroke.

Chancellor BK, Ishida K.

J Neuroophthalmol. 2016 Dec 8. [Epub ahead of print]

PMID:
27941401
20.

Causes of Death in Anticoagulated Patients With Atrial Fibrillation.

Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E.

J Am Coll Cardiol. 2016 Dec 13;68(23):2508-2521. doi: 10.1016/j.jacc.2016.09.944.

PMID:
27931607
Items per page

Supplemental Content

Loading ...
Support Center